Top Markets
#1 Merlin's Seal BTC Merlin's Seal BTC +42.87%
#2 Unipoly Unipoly +41.52%
#3 Useless Coin Useless Coin +30.00%
#4 0G 0G +29.98%
#5 SAFEcoin SAFEcoin +29.29%
#6 Zora Zora +22.15%
#7 Seeker Seeker +21.36%
#8 Dogs Dogs +21.33%
#9 Pons Pons +20.75%
#10 Fake World Assets Fake World Assets +17.63%
Coin of the day
Merlin's Seal BTC Merlin's Seal BTC
Settings
Language
ENGLISH
Currency
USD
Theme
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

3378
Rank in Stocks #13036
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and... Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company's product pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein that is in Phase IIa clinical trials for the treatment of EBV+ non-Hodgkin lymphoma, acral/mucosal subtype melanoma, relapsed/refractory melanoma post-PD-1 therapy, and Biliary tract cancer; HX044, a CTLA-4/SIRPa bifunctional fusion protein which is in Phase Ia for the treatment of solid tumours; HX301, a novel oral multi-kinase inhibitor that is in Phase IIa for the treatment of glioblastoma; and HX111, an ADC drug candidate to treat solid tumours. It is also developing proprietary in-house platforms, such as the VersatiBody, a multi-functional antibody discovery platform that generated two clinical-stage FIC bifunctional fusion proteins (HX009, HX044), as well as completed the preclinical development of multiple ADC/bispecific molecules, including FIC PPC HX111 (OX40-ADC) and HX116 (PD-L1×VEGF BsAb-ADC); and the autoRx40, an autoimmune therapeutic platform, completing the design of multiple candidate molecules in the field of autoimmune diseases, such as HX035, HX038, and HX138. Hanx Biopharmaceuticals (Wuhan) Co., Ltd. was incorporated in 2014 and is headquartered in Wuhan, China.
Share Price
$3.91
Market Cap
$524.79M
Change (1 day)
-0.71%
Change (1 year)
-
Country
CN
Trade Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378)

Category

Healthcare
Revenue for Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378)
Revenue in Aug 2026 TTM: 0
According to Hanx Biopharmaceuticals (Wuhan) Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Hanx Biopharmaceuticals (Wuhan) Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH